2 completed, 2 not yet recruiting. 2 Not applicable, 1 Early Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Not yet recruiting 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Zhang Xiaofeng,MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer anti-EX02 CAR T cells - Pancreatic Cancer, Advanced Biliary Cancer | Early Phase 1 | Not yet recruiting | Zhang Xiaofeng,MD | 6 | 2024-01-01 | 2024-01-09 |
| Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1) Tegoprazan 50 mg, tablets, orally, qd, Esomeprazole 20mg BID, Tegoprazan 50 mg, tablets, orally, bid - Helicobacter Pylori Infection | Phase 4 | Completed | Zhang Xiaofeng,MD | 370 | 2023-11-01 | 2026-01-16 |
| Canagliflozin With Gemcitabine in Pancreatic Carcinoma Canagliflozin and Gemcitabine, Gemcitabine - Pancreatic Cancer | Not applicable | Not yet recruiting | Zhang Xiaofeng,MD | 20 | 2023-10-01 | 2023-06-15 |
| Comparison of Oral Lactulose Versus Polyethylene Glycol for Bowel Preparation in Low-risk Patients Lactulose oral solution, PEG - Colonic Neoplasms | Not applicable | Completed | Zhang Xiaofeng,MD | 255 | 2022-01-08 | 2022-12-13 |
Pancreatic Neoplasms (2) · Colonic Neoplasms (1)
Amoxicillin (1) · BID protein, human (1) · Canagliflozin (1) · Esomeprazole (1) · Gemcitabine (1) · Lactulose (1) · Tablets (1) · tegoprazan (1)
China (3)